Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Milk thistle & HIV

This article was originally published in The Tan Sheet

Executive Summary

"Milk thistle in commonly administered dosages should not interfere with indinavir therapy in patients infected with" HIV, researchers report in May Pharmacotherapy. Stephen Piscitelli, et al., National Institutes of Health, conducted prospective open-label study of 10 healthy volunteers and found an insignificant 9% reduction in presence of HIV drug indinavir after three weeks of dosing with milk thistle. Participants received four doses of indinavir 800 mg at baseline, then took 175 mg milk thistle (containing 153 mg silymarin) three times/day for three weeks. In similar research, Piscitelli et al. had shown HIV drug interactions with garlic, St. John's wort (1"The Tan Sheet" Dec. 10, 2001, p. 11)...

You may also be interested in...



Garlic Supplements, Protease Inhibitor Interactions Troublesome – NIH Study

A National Institutes of Health study finding garlic supplements reduce plasma concentration levels of an HIV protease inhibitor by approximately 50% could spur drug interaction warnings on such supplements

Did Sarepta Need To Tell Investors About Its Vyondys 53 Dispute Resolution Request?

Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.

Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning

Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.

Topics

UsernamePublicRestriction

Register

PS094123

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel